Instem plc
("Instem" or the "Company")
Director/PDMR Dealings
Instem (AIM: INS.L), a leading provider of IT solutions to the global life sciences market, has been notified that, on 11 October 2021, Nigel Goldsmith, Chief Financial Officer, acquired 2,500 ordinary shares in the Company at a price of 825p per share. Following this acquisition, Mr. Goldsmith is interested in 2,500 ordinary shares, representing 0.01 per cent. of the ordinary shares in issue.
For further information, please contact:
| Instem plc | via Walbrook |
| Phil Reason, CEO | |
| Nigel Goldsmith, CFO | |
| | |
|
Singer Capital Markets (Nominated Adviser & Broker) |
+44 (0) 20 7496 3000 |
| Peter Steel Rachel Hayes Alex Bond | |
| | |
|
Walbrook Financial PR |
+44 (0) 20 7933 8780 |
| Tom Cooper | |
| Nick Rome
| |
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services now address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.
To learn more about Instem solutions and its mission, please visit www.instem.com.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||
| a) | Name | Nigel Goldsmith | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer and PDMR | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Instem plc | |
| b) | LEI | 213800PILYUFNNROQX68 | |
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary shares of 10 pence each
GB00B3TQCK30 | |
| b) | Nature of the transaction | Purchase of ordinary shares | |
| c)
| Price(s) and volume(s)
| Price | Volume |
| 825 pence | 2,500 | ||
| d)
| Aggregated information
- Aggregated volume
- Price
| N/A - single transaction | |
| e) | Date of the transaction | 11/10/2021 | |
| f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
